FDA delays response to Nammex’s Mushroom product labeling petition
The US Food and Drug Administration has declined to respond to a Citizen Petition by North American Reishi Ltd (“Nammex”) on the labeling and sale of food and supplements containing fungal ingredients, citing “competing agency priorities”.